QHP Converts $1.1B Azurity Hold Into Continuation Vehicle

Quality Home Products Capital just pulled off a move that's becoming more common in private equity's upper echelons: instead of selling a prized asset, the Boston-based firm is keeping it — and giving early investors the chance to bail.

The firm announced Tuesday it's formed a $1.1 billion continuation vehicle for Azurity Pharmaceuticals, the specialty drug maker it's backed since 2018. The structure lets limited partners who want liquidity now take their chips off the table, while those willing to ride out another hold cycle can stay invested alongside new capital.

It's a bet that Azurity — which sells treatments for rare pediatric conditions and hard-to-administer drugs — is worth more if QHP keeps building rather than shopping it to the highest bidder. The firm isn't saying what valuation the continuation vehicle implies, but the $1.1 billion figure includes both rollover equity and fresh commitments.

"We've built something genuinely differentiated in specialty pharma," said Michael Thompson, Managing Partner at QHP, in a statement. "The continuation vehicle gives us the runway to fully realize that value without forcing an exit on a timeline dictated by fund life." Translation: we think we can make more money if we don't have to sell right now.

A decade ago, continuation vehicles were a niche corner of secondaries markets. Now they're standard operating procedure for sponsors sitting on assets they don't want to sell.

The mechanics are straightforward. A GP creates a new fund — the continuation vehicle — and uses it to buy the asset from the existing fund. LPs in the old fund can either roll their stakes into the new vehicle or take cash. The new vehicle typically includes outside investors, often secondaries buyers like Lexington Partners or Coller Capital, who provide the liquidity.

For GPs, it solves a painful problem: what to do when a company is performing well but market conditions for a sale are lousy, or when the business needs another 3-5 years to hit its full potential but the fund holding it is out of time. For LPs, it creates a choice — take liquidity now at a negotiated price, or re-up for another ride.

The structure took off after 2020. Jefferies estimates continuation vehicle volume hit $38 billion in 2024, up from $12 billion in 2020. Part of that growth is necessity — funds raised in 2017-2019 are hitting their exits now, and IPO windows have been unreliable. But part of it is strategy. Sponsors have realized that if they've built real operating capability inside a business, selling to another PE firm or going public might just hand value to someone else.

Azurity isn't a household name, but it's carved out a defensible position in a corner of pharma most companies ignore. The business focuses on specialty and orphan drugs — treatments for rare diseases, pediatric conditions, and medications that require complex delivery mechanisms.

One of its flagship products is sodium phenylbutyrate, a treatment for urea cycle disorders, a rare metabolic condition that mostly affects children. The company also markets drugs that address niche needs like oral suspensions for patients who can't swallow pills. These aren't blockbuster therapies, but they generate steady revenue because they serve small, underserved patient populations with limited alternatives.

QHP acquired Azurity — then known as Silvergate Pharmaceuticals — in 2018 from previous PE owner Alta Partners in a deal reportedly valued around $400 million. Since then, the firm has executed a buy-and-build strategy, acquiring complementary drug portfolios and expanding Azurity's commercial reach.

The challenge with selling a company like Azurity is that traditional pharma acquirers don't get excited about orphan drugs unless they're gene therapies with billion-dollar runways. Strategic buyers want scale. Azurity's products generate solid margins on small volumes — great for a PE-owned business, harder to justify for a Big Pharma development team.

QHP's decision to hold rather than sell reflects broader headwinds in healthcare M&A. Specialty pharma deal volume in 2025 was down 22% year-over-year, according to PitchBook, as buyers balked at elevated purchase price multiples and regulatory scrutiny intensified around drug pricing.

The continuation vehicle gives QHP room to execute on a few strategic angles that wouldn't pay off in a near-term exit.

First, the firm can keep building out Azurity's portfolio through smaller acquisitions. Specialty pharma is fragmented — dozens of small companies own one or two niche drugs but lack the infrastructure to commercialize them effectively. QHP can acquire those assets, plug them into Azurity's existing sales and distribution network, and generate returns through operational leverage rather than price appreciation.

Second, holding longer gives Azurity time to push drugs deeper into their lifecycle curves. Many of the company's treatments are still in early commercialization phases. Staying private avoids the quarterly earnings pressure that comes with being owned by a public acquirer or going public directly.

Third — and this is the quiet part — continuation vehicles let sponsors reset the clock on carried interest. If QHP had sold Azurity this year, the profit split with LPs would be based on the original 2018 entry price. By moving the asset into a new fund at today's valuation, future gains get calculated from this $1.1 billion starting point. That's favorable for the GP if the business keeps growing.

Not every LP will want to roll into the continuation vehicle. Some need liquidity to meet their own distribution commitments. Others might be skeptical that another 4-5 year hold will generate enough incremental return to justify the time value of money. The secondaries buyers stepping in to provide liquidity aren't doing so out of charity — they're pricing the stakes they're buying at a discount to what the GP thinks the business is worth.

That pricing tension is where continuation vehicles can get contentious. LPs who want to sell have limited negotiating leverage — the GP sets the terms, and the alternative is often "take this price or keep waiting." Some institutions have pushed back, arguing that continuation vehicles can disadvantage LPs who need liquidity while letting GPs extend their management fees.

The rise of continuation vehicles isn't just about individual deals — it reflects a broader shift in how private equity firms think about hold periods and value creation.

Traditional PE was a 5-7 year model: buy, fix, sell, repeat. But the industry's best performers increasingly look more like long-term operating companies that happen to be structured as funds. Vista Equity Partners, for instance, holds software companies for a decade or more, layering on acquisition after acquisition. Thoma Bravo does the same thing. The value isn't in the financial engineering — it's in the operational compounding.

Continuation vehicles give firms a tool to pursue that strategy without blowing up their LP relationships. They're a compromise: LPs who want liquidity get it, LPs who believe in the long-term thesis can stay invested, and the GP keeps control.

The skeptical read on continuation vehicles is that they let GPs kick the can down the road when they should be admitting a hold isn't working. If a company has been in the portfolio for seven years and still isn't ready for exit, maybe the problem isn't market timing — maybe it's the business.

There's also a performance measurement problem. If a GP can keep resetting the basis through continuation vehicles, it's harder for LPs to evaluate whether the original investment thesis was right. Did QHP generate a great return on Azurity, or did it just extend the hold until market conditions were favorable enough to declare victory?

QHP didn't disclose which secondaries buyers or institutional investors are anchoring the continuation vehicle. Typically these transactions involve a handful of large secondaries funds — Lexington Partners, Ardian, and Coller Capital are the most active — plus some long-horizon LPs who want exposure to the asset.

Secondaries buyers have become critical players in making continuation vehicles viable. They provide the liquidity that lets selling LPs exit while also validating the GP's valuation through their own underwriting. If a secondaries buyer is willing to write a $300 million check at the proposed valuation, that signals at least some third-party confidence in the pricing.

Whoever the buyers are, they're betting QHP can grow Azurity's EBITDA materially over the next hold period. Specialty pharma businesses like this typically trade at 10-15x EBITDA in M&A markets. If the continuation vehicle is pricing the business at $1.1 billion, that implies somewhere around $70-110 million in current EBITDA — solid for a company operating in niche therapeutic areas.

The upside case for the new investors is that QHP can double that EBITDA through acquisitions and organic growth over the next five years. If they do, and exit multiples hold steady, the continuation vehicle generates a respectable mid-teens IRR even after accounting for management fees.

The fact that QHP chose a continuation vehicle instead of pursuing a strategic sale or IPO tells you something about how sponsors are reading the current exit landscape.

Public markets aren't hostile to healthcare, but they're selective. Investors want growth stories with clear paths to scale. Azurity's business model — steady cash flow from niche drugs — is more suited to private ownership than public market scrutiny.

Strategic M&A is possible, but pricing is the sticking point. Big Pharma buyers have capital to deploy, but they're disciplined about multiples. If QHP thinks Azurity is worth $1.1 billion and strategics are offering $900 million, the math favors holding.

Sponsor-to-sponsor sales are always an option, but they're hard to execute when the seller knows the business intimately and the buyer has to underwrite with less information. QHP has been inside Azurity for eight years — they know where the value is. A new buyer would demand a discount for that information asymmetry.

The continuation vehicle closes a chapter for some LPs and opens a new one for others. Azurity itself likely won't see much operational change — same management team, same strategy, same backing sponsor.

What does change is the pressure to perform. The new investors are pricing the business on a forward-looking basis, which means QHP needs to deliver the growth it's promising. If EBITDA doesn't materialize over the next few years, the continuation vehicle could end up being a mistake — extending a hold on a mediocre asset rather than crystallizing a good return when it was available.

For the broader market, the deal is another data point in the normalization of continuation vehicles. They're no longer a sign that something went wrong — they're a deliberate strategic tool. Whether that's good for LPs or just good for GPs depends on who you ask.

One thing's certain: expect to see more of them. When GPs can keep their best assets, reset economics, and still give LPs liquidity, the incentives all point in one direction. The question is whether the returns justify the extended hold periods — or whether the industry is just getting better at deferring the day of reckoning.